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OBJECTIVES This study was designed to assess the effect of abciximab on platelet and leukocyte deposition
60 min after stent insertion in nonhuman primates.
BACKGROUND Although it is well established that abciximab improves both short- and long-term clinical
outcomes after stent placement, there have been no studies assessing its effect on early platelet
and leukocyte deposition.
METHODS Cynomolgus monkeys were pretreated with aspirin and either saline or a 0.4 mg/kg bolus of
abciximab, and then subjected to angioplasty and Palmaz-Schatz stent placement in the
common iliac artery or abdominal aorta. After 60 min, animals were euthanized and the
stented artery was evaluated by immunohistochemistry and morphometry.
RESULTS Complete occlusion of the stented vessel with a thin fibrin(ogen) meshwork and trapped
blood occurred in two saline-treated and two abciximab-treated animals. In the four
remaining saline-treated animals, a layer of erythrocytes trapped in a network of fibrin(ogen)
was noted close to the vessel wall, and this was covered by a layer of large, irregular platelet
thrombi. Leukocytes formed a monolayer on top of the platelets and near stent struts. In the
four remaining abciximab-treated animals, the mean erythrocyte area was 65% smaller (p 
0.070), the platelet aggregate area was 89% smaller (p 0.049) and the luminal area was 59%
larger (p  0.004). A monolayer of leukocytes also formed on top of the platelets and near
stent struts.
CONCLUSIONS In control stented blood vessels in this study, platelet thrombi formed not at the vessel wall,
but on top of an erythrocyte-rich layer, and platelets recruited leukocytes. Abciximab
decreased the size of platelet thrombi, but did not prevent leukocyte recruitment. (J Am
Coll Cardiol 2002;40:360–6) © 2002 by the American College of Cardiology Foundation
Adding abciximab treatment to coronary artery stent inser-
tion has been demonstrated to have both short- and
long-term beneficial effects, including prevention of isch-
emic complications during the first 30 days (1), improved
microcirculatory function and recovery of myocardial func-
tion (2), prevention of the development of restenosis in
diabetic patients (3) and reduced one-year mortality (4).
Proposed mechanisms to explain these benefits include
inhibition of platelet aggregation, reduced platelet-mediated
thrombin generation, reduced release from platelets of
vasoactive agents, reduced platelet-mediated clot retraction
and reduced intimal hyperplasia in response to vascular
injury (reviewed in Coller [5], Coller [6] and Smyth et al.
[7]). It is also possible that abciximab’s effects are mediated
through inhibition of platelet-leukocyte interactions (8),
because such interactions have been implicated in thrombin
generation, microcirculatory damage and the development
of intimal hyperplasia after vascular injury (reviewed in
Coller [5] and Smyth et al. [7]). Moreover, abciximab has
been reported to interact with an activated form of the
leukocyte integrin M2, which has been implicated in the
development of intimal hyperplasia after vascular injury (9).
To better understand the effect of abciximab on platelet
and leukocyte deposition at the site of stent insertion, we
performed angioplasty and stent insertion in arteries of
nonhuman primates treated with saline or abciximab. We
evaluated the arteries 60 min after stent insertion because
platelet-leukocyte interactions are prominent at that time
point in other models of vascular injury (7), and there have
been very few studies of the blood cell interactions that
occur within the first hour after stent insertion. We chose
not to treat the animals with heparin because: 1) we wished
to assess the effect of abciximab on thrombin generation at
the site of vascular injury, and heparin’s anticoagulant effects
might confound such assessment; 2) heparin has demon-
strated inconsistent results in protecting against acute stent
thrombosis in in vitro and animal models (10–14); and 3)
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heparin is known to activate platelets in vitro (15) and in
vivo (16) and to enhance in vivo platelet-leukocyte aggre-
gate formation (16).
METHODS
Platelet function and coagulation assay. Platelet function
was measured with a modified version of the rapid platelet
function assay (RPFA) (Accumetrics, San Diego, Califor-
nia) (17) using 20 M adenosine diphosphate as the
agonist.
Animal preparation and surgical procedure. Twelve male
cynomolgus monkeys (Maccaca fasicularis) weighing 3.3 to
8.5 kg were treated with aspirin (10 mg/kg/day by mouth)
starting three or four days before the procedure. Animals
were sedated with 10 mg/kg ketamine, intubated and
mechanically ventilated with 2% isoflurane-98% O2 at a
minute ventilation of 1.5 l/min. 111Indium-labeled autolo-
gous platelets from donor monkeys (18) were injected
through a sheath in the jugular vein 75 to 110 min before
the injury. An arterial sheath (6 to 7 French) was placed in
the carotid artery to facilitate the placement of the guide
catheter and the angioplasty catheter. An angiogram was
performed to measure the vessel diameter. Animals were
treated with either saline or a 0.4 mg/kg intravenous bolus
of abciximab.
Vascular injury was performed with a 3 to 4 mm
semicompliant angioplasty balloon (Olympix, Cordis, Mi-
ami, Florida; Valor, Cordis; ACS lifestream, Advanced
Cardiovascular Systems, Santa Clara, California). The ves-
sel was stretched to 1.4 times its initial diameter by inflating
the balloon three times for 1 min. Mean (SD) inflation
pressures were 7.3  2.1 atms in the abciximab group and
6.5  1.1 atms in controls (p  0.4). Immediately thereaf-
ter, a Palmaz Schatz stent was deployed by stretching the
vessel to 1.5 times its initial diameter by balloon inflation
three times for 30 s. Mean inflation pressures were 12.7 
1.5 atms and 13.2  1.3 atms in the abciximab and control
groups (p  0.6). One hour after stent deployment, animals
were euthanized and perfusion-fixed with saline and 4%
paraformaldehyde. The vessels containing the stents were
harvested as 1.2-cm-long segments, weighed and analyzed
for 111Indium in a gamma spectrometer; they were then
further fixed in 4% paraformaldehyde for histology.
Blood sampling. Blood was drawn through the jugular
vein immediately after jugular catheter placement, after
angiography, 10 min after drug injection and 60 min after
stent deployment.
Histology and immunohistochemistry. Specimens were
dehydrated and then infiltrated and embedded in methyl-
methacrylate. Stents were cut into three 4-mm-long seg-
ments using a diamond-edged saw (Isomet, Buehler, Lake
Bluff, Illinois). The central portion (containing the hinge
region) was not studied, and sections were cut from each of
the two other segments for each stain. Sections (5 to 8 m)
for leukocyte analysis were stained with hematoxylin and
eosin, whereas sections for histochemistry were soaked in
3% H2O2 and then blocked with 2% ovalbumin in
phosphate-buffered saline (PBS). After washing in PBS,
sections were incubated with a primary antibody for 2 h at
37°C, and then with a biotinylated species-specific second-
ary antibody for 20 min at 22°C. The slides were reacted
with horseradish peroxidase-conjugated streptavidin, devel-
oped with diaminobenzidine (Biogenex, San Ramon, Cal-
ifornia) and counterstained with hematoxylin.
Antibodies to human P-selectin and PSGL-1 were from
Pharmingen (San Diego, California); fibrin(ogen) from
Behring (King of Prussia, Pennsylvania); platelet factor-4
and plasminogen activating inhibitor-1 (PAI-1) from
American Diagnostica (Greenwich, Connecticut); tissue
plasminogen activator (t-PA) and tumor necrosis factor-
alpha from Accurate Chemical (Westbury, New York);
platelet-derived growth factor A chain from Santa Cruz
Biotechnology (Santa Cruz, California); interleukin-1-beta
from Harlan Sera-Lab (Loughborough, United Kingdom);
thrombin/prothrombin from Dr. Peter Harpel (19); and
tissue factor (TF) from Dr. Yale Nemerson (20).
Histomorphometry. Vessel injury produced by the stent
was determined using an injury score modified from
Schwartz et al. (21). An observer blind to the treatment
groups performed the histomorphometric analysis on one
representative section from each animal. Using Image Pro
plus (Media Cybernetics, Silver Spring, Maryland), the
following areas were determined: 1) the lumen; 2) inside the
internal elastic lamin (IEL); 3) the erythrocyte-rich layer;
and 4) the platelet thrombi. The number of leukocytes in
two sections from each animal were counted and normalized
for the circumference of the vessel.
Electron microscopy. Segments were cut from blood ves-
sels of one control animal and one animal treated with
abciximab (Numbers 1 and 5, Table 1) and treated with
methyl acetate to dissolve the methacrylate. After treatment
with 2% glutaraldehyde and 1% osmium tetroxide, the tissue
was dehydrated and embedded in EMbed 812 (EMS, Fort
Washington, Pennsylvania). Ultrathin sections were stained
with uranyl acetate and lead citrate.
Statistics. Data are described as mean  SD. Individual
values of hematologic and coagulation measurements are
shown in Table 1. Statistical analyses of injury score and
histomorphometric data were performed using two-tailed t
Abbreviations and Acronyms
GP  glycoprotein
IEL  internal elastic lamina
PAI-1  plasminogen activating inhibitor-1
PBS  phosphate-buffered saline
PSGL-1  P-selectin glycoprotein ligand-1
RPFA  rapid platelet function assay
TF  tissue factor
t-PA  tissue plasminogen activator
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tests of differences in means for unequal variances. The
exact p values for each test are reported as a guide to
interpreting the results, but no claims of statistical signifi-
cance are made because these are exploratory analyses.
RESULTS
Arterial injury and stenting. The study was conducted on
two separate groups of animals. The first group (eight
animals, 5.2 to 8.5 kg) had iliac arteries that were large
enough to accommodate stents (2.5 to 3 mm). The second
group (four animals) was smaller (3.3 to 4.7 kg) and had
smaller iliac arteries (2 mm), and so stents were placed in
the aortas (2.5 to 3.0 mm). The mean (SD) diameters of
the stented vessels were 2.8  0.3 mm in the controls and
2.8  0.2 mm in the abciximab group.
The first four animals from the first group (two controls
and two abciximab-treated) were found to have occluded
stents at the time of harvest. Histologic analysis of multiple
sections revealed blood trapped in a loose fibrin mesh
occluding the vessel. Platelet thrombi were prominent near
the stent in one of the control animals, but not in the other
three. Stent struts were not properly apposed to the blood
vessel wall in both abciximab-treated animals (for the total
circumference in one animal and for half the circumference
in the other), indicating poor stent deployment (data not
shown). These animals were not included in the statistical
assessment because the age of the occlusions could not be
determined, and the histomorphometric pattern was funda-
mentally different from that of the other animals (as
described later).
The mean injury scores in the eight animals included in
the statistical assessment were similar in control and abcix-
imab groups (2.15 0.31 vs. 2.33 0.17, p 0.25) (Table 1).
Hematology, coagulation and platelet function assays.
Hematology and coagulation values were similar among
animals within both groups before and after the experiments
(Table 1).
Rapid platelet function assay slope values increased at the
end of the experiment in all of the control animals (mean
38%). Ten minutes after abciximab administration, the
RPFA values in all abciximab-treated animals decreased to
0; at 60 min, the RPFA values in animals 5 to 7 remained
0, but the value in animal 8 was 26% of the baseline value.
Histologic analysis. Figure 1 shows representative sections
from one animal in each group. In all four animals in the
control group there was a layer of erythrocytes within a fine
network of fibrin close to the vessel wall along the entire, or
nearly entire, circumference of the vessel (Fig. 1A, left
panel). On top of this layer was a variably thick layer of
fibrin, and on top of the fibrin layer were large, irregular
platelet thrombi (Fig. 1A, center panel). In some animals,
platelet thrombi were also identified near the stent struts.
Numerous leukocytes deposited on top of the outermost
layer of platelets making up the thrombi (Fig. 1A, right
panel). In addition, small numbers of leukocytes wereTa
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present in irregular clusters and in isolated linear arrays near
the stent struts and within the platelet thrombi (Fig. 1,A,
center and right panels). In abciximab-treated animals (Fig.
1B) the erythrocyte-rich areas and platelet thrombi ap-
peared smaller. Leukocytes also lined the vessel wall of the
abciximab-treated animals, and leukocytes were also present
in small thrombi adjacent to the stent struts.
By histomorphometry, the areas inside the IEL were
similar between the control and abciximab-treated groups
(9.51  1.56 mm2 vs. 10.7  1.89 mm2; p  0.36) (Table
1), indicating that the blood vessels in the two groups were
similar in size. In the abciximab-treated animals, however,
the average erythrocyte-rich area was 65% smaller, the
average area of platelet aggregates was 89% smaller and the
average luminal area was 59% larger. The differences in
erythrocyte-rich areas in the abciximab-treated animals and
controls were not as great as the differences in platelet
thrombi areas and luminal areas (erythrocyte areas 1.05 
0.84 mm2 vs. 3.01  1.46 mm2 [p  0.070]; platelet areas
0.05 0.04 mm2 vs. 0.45 0.25 mm2 [p 0.049]; luminal
areas 9.64  1.21 mm2 vs. 6.06  1.01 mm2 [p  0.004]).
The mean number of leukocytes deposited was 55% lower in
the abciximab-treated group, but the variability between
animals in the control group was considerable (33  12 per
mm vs. 74  76 per mm; p  0.36).
Transmission electron microscopy performed on control
animal 1 confirmed the presence of exuberant platelet
thrombi, with variable loss of platelet granules and discern-
ible borders between individual platelets (Figs. 2A and 2B).
Electron micrographs from animal 5, which was treated
with abciximab, revealed a single layer of variably spread
platelets adherent to the damaged blood vessel, just above
the IEL (Figs. 2C and 2D).
In the sections from the control animals, the outermost
surface of the platelet aggregates, as well as the majority of
the areas within the aggregates, stained positive for platelet
factor 4, P-selectin (Fig. 3A), CD40 ligand (Fig. 3C), von
Willebrand factor, PAI-1, interleukin-1-beta, tumor necro-
sis factor-alpha and platelet-derived growth factor A chain.
Antibody to fibrin(ogen) stained the periphery of the
platelet aggregates, the thin fibrin strands throughout the
erythrocyte layer, and the thick fibrin layer. Antibodies to
prothrombin/thrombin, and to t-PA gave patterns similar
to those found with the antibody to fibrin(ogen). Staining
Figure 1. Histologic assessment of stented blood vessels from a control animal (Number 1) (A) and an abciximab-treated animal (Number 5) (B). Some
of the cut stent struts (S) remain in the sections (black rectangles) and in some areas the spaces occupied by the stent struts can be identified (unoccupied
rectangles). Sections were stained with hematoxylin and eosin. Left column is 12.5 magnification, the center column 100 magnification and the right
column is400 magnification. E/F erythrocytes and fibrin; L leukocytes; M smooth muscle in the media of the blood vessel; P platelet thrombi.
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for TF also gave a pattern that was very similar to that with
the antibody to fibrin(ogen), but in addition, granulocytes
gave weak staining and monocytes gave more intense
staining (Fig. 3E). Leukocytes, but not platelets, stained
positive for P-selectin glycoprotein ligand-1 (PSGL-1).
In abciximab-treated animals, the antibodies to platelet
alpha-granule and membrane proteins stained a discontin-
uous layer of platelets on the blood vessel surface (Figs. 3B
and 3D). Antibodies to fibrin(ogen) and prothrombin/
thrombin also stained very weakly. Tissue factor antigen was
present as a discrete but thin layer on the vessel wall; in
addition, individual neutrophils stained variably positive and
monocytes stained strongly positive (Fig. 3F). Leukocytes
stained positive for PSGL-1.
111Indium-platelet deposition. In the control group and
three of the four abciximab-treated animals, the platelet
deposition values correlated well with the platelet thrombus
area by histomorphometry. In animal 8, however, platelet
deposition was high relative to the platelet thrombus area.
This was the only animal to sustain loss of a segment of the
vascular wall in response to the injury, and thus radiolabeled
platelets may have been trapped outside the lumen of the
blood vessel.
DISCUSSION
Acute occlusions of stented vessels. The first two animals
in both the saline- and abciximab-treated groups had
occluded stents at 60 min, making it impossible to establish
the time of occlusion. Histomorphometry demonstrated
that the majority of the occluding thrombus consisted of a
thin fibrin mesh entrapping blood. Stent deployment was
good in both control animals, but was suboptimal in both
abciximab-treated animals. It is notable that abciximab did
not prevent the occlusion, despite preventing platelet aggre-
gate formation.
Erythrocyte-rich area near blood vessel wall. In control
animals, the presence of a layer of blood trapped in a fine
fibrin network adjacent to the vascular wall was both
striking and unexpected. The vascular wall itself showed
little evidence of thrombus formation, although there was
some leukocyte deposition and platelet thrombus formation
near the stent struts. We could not find previous descrip-
tions of studies in which blood vessels were analyzed 60 min
after stent placement, but Carter et al. reported mural
thrombus, with morphology very similar to what we ob-
served, 24 h after stent placement in porcine coronary
arteries (22). Of note, Carter et al. treated their animals
with heparin, making it unlikely that our results are due to
our not using heparin. We propose that stent insertion leads
to a reduction in blood flow immediately adjacent to the
wall, which favors thrombin generation and the develop-
ment of a fibrin network that can trap the nearby layer of
stagnant blood. Platelet thrombi can then form on top of
that surface. The trapped layer of blood may ultimately serve
as a scaffold for subsequent smooth muscle cell migration,
leading to intimal hyperplasia (22).
There was a trend toward a smaller mean area of trapped
erythrocytes with abciximab treatment, and in one animal
there was no layer at all. The most plausible explanation for
abciximab’s effect is that it decreases platelet thrombus
formation at the sites where the stent struts contact the
blood vessel wall and thus decreases thrombin generation
and fibrin formation.
Platelet thrombi. The large platelet thrombi originated
not at the blood vessel wall, but rather on top of the trapped
blood cell layer. Electron microscopy confirmed that the
thrombi were composed almost exclusively of platelets, and
that the platelets in the deeper regions of the thrombi had
coalesced.
Abciximab treatment reduced platelet thrombus forma-
tion area by 89%, but did not prevent the deposition of a
discontinuous monolayer of platelets. These results are
consistent with in vitro and in vivo evidence in other
systems, demonstrating that abciximab blocks platelet-
platelet interactions, but not platelet adhesion (5,6).
Tissue factor antigen was present on the outer surface of
the platelet aggregates in the control animals and on the
surface of the platelet monolayer in the abciximab-treated
animals. These observations are consistent with the data of
Giesen et al. (23) and Rauch et al. (24), who demonstrated
that TF circulates in blood in association with small lipid
vesicles and that these TF-rich vesicles can bind to platelet
aggregates that form on collagen-coated surfaces in vitro.
Thus, platelet aggregates can recruit blood-borne TF, pro-
viding a mechanism to initiate thrombin generation even in
Figure 2. Electron micrographs of stented blood vessels from one control
animal (Number 1) (A and B) and one abciximab-treated animal (Number
5) (C and D). An exuberant platelet aggregate is present in A; thin fibrin
strands with a thicker layer of fibrin and platelet aggregates with an
adherent neutrophil are present in B; in C and D a single layer of spread
platelets (arrows) adhere directly to the damaged blood vessel wall.
Original magnifications are 2,600 in A, 1,600 in B, 2,400 in C and
11,000 in D. IEL  internal elastic lamina.
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the absence of exposing tissue factor in the lipid-rich core of
an atherosclerotic lesion or in the adventitia.
Leukocyte-platelet interactions. In control animals, there
was a dense layer of leukocytes on the outside of the platelet
aggregates. Leukocytes were also found in clusters and in
linear arrays near the stent struts, in the trapped blood layer
and within the platelet aggregates. Abciximab-treated ani-
mals had less extensive platelet aggregate formation and
thus had fewer leukocytes associated with these aggre-
gates. Abciximab did not, however, prevent the binding
of leukocytes to the platelet monolayer on the surface of
the damaged blood vessel or to sites adjacent to the stent
struts. These data are consistent with our findings in a
vascular injury model in mice lacking glycoprotein (GP)
IIb/IIIa and V3, where leukocytes still deposited on
top of the platelet monolayer 60 min after injury to the
femoral artery (7). Thus, other receptors can support
platelet-leukocyte interactions, including but not limited
to the interaction between P-selectin on activated plate-
lets and PSGL-1 on leukocytes (reviewed in Coller [5])
and perhaps platelet GP Ib with leukocyte M2 (25).
Our data do not, however, exclude the possibility that GP
IIb/IIIa- and/or V3-mediated interactions may con-
tribute to firm adhesion of leukocytes on platelets or
platelet-dependent leukocyte activation (8).
The platelet thrombi and platelet-leukocyte interactions
that occur in the region of stent insertion may serve as an
ongoing source of platelet microparticles, platelet emboli
and platelet-leukocyte emboli that may damage the distal
microcirculation. Similarly, thrombin generated on the
platelet surface and serotonin and thromboxane A2 released
from platelets may further compromise the distal circula-
tion. Both human and animal model data support a role for
abciximab in decreasing microcirculatory damage after vas-
cular injury (2,26), which may be explained at least in part
by the smaller platelet thrombi we observed at the site of
stent insertion. A protective effect of abciximab on the
microcirculation may also contribute to abciximab’s long-
term mortality advantage (6) if microcirculatory damage
ultimately results in patchy fibrosis, electrical instability and
increased risk of sudden death. Thus, to understand the full
effects of stent insertion it is important to consider not only
large-vessel obstruction at the site of injury, but also the
distal effects on the microcirculation initiated by the original
injury.
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